| INTRODUCTION
Bleeding disorders (BD) such as von Willebrand disease (VWD), coagulation factor deficiencies and platelet disorders (PD) are frequently reported in adolescents with heavy menstrual bleeding (HMB). 1, 2 Although the overall prevalence rates of BD are comparable in adolescent and adult females with HMB, 3 the bleeding phenotype and provider interventions may be different. Potential differences may include younger age at presentation with symptoms in adolescents. At any age, lack of patient/provider awareness can cause delay in diagnosis and more bleeding complications. Studies of females with diagnosed BD have consistently found that although bleeding symptoms often began during childhood and adolescence, the diagnosis was most often not made until adulthood. 4, 5 Such delays in care seeking and BD diagnosis may lead to delay in therapy, education and counsel- 
| MATERIALS AND METHODS
The history for bleeding problems, (v) history of gynaecological abnormalities and reproductive outcomes, and (vi) history of menopause and menopause-related treatment for bleeding. Primarily registration data are included in this analysis; height and weight were included from the annual form to calculate body mass index (BMI). The protocol was reviewed and approved by institutional review boards at CDC and the individual sites. Menarche was self-reported by the study participants.
To minimize recall bias, HMB analyses were restricted to postmenarchal females and excluded self-identified postmenopausal women.
There was a delay in diagnosis of a BD if age at diagnosis was greater than the age at first bleed in years; the median difference in years was also calculated.
For this study analysis, we compared the study population of postmenarchal adolescents <18 years old and premenopausal adults >/= 18 years old who had a BD and HMB enrolled in the female UDC project. Patient demographics, diagnoses, bleeding symptoms, provider interventions, medical and surgical treatment for HMB, and treatment of anaemia as listed in Tables 1, 2 and 3, were compared for adolescents and adults.
| Statistical analysis
The statistical analysis for the study was done in 2 steps. and thrombocytopenia) in 11 (4%); 9 (3%) patients had unspecified BD. (Table 1) . No statistically significant difference in BD diagnoses was detected between the 2 groups. The majority had a single BD diagnosis (n = 249, 92.6%), few (n = 11, 4.1%) had multiple. The median age at first bleed (any bleed) was 10 years (IQR = 10 years) and the median age at diagnosis of BD was 14 years (IQR = 13 years).
The difference between the median age at first bleed in adolescents (9 years; IQR 10) when compared to adults (10.5 years; IQR 10), was not statistically significant (P = .46). The median age at diagnosis of BD was 12 (IQR 7) for adolescents vs 16 (IQR 16) for adults (P < .0001).
Forty-five adolescents (57%) and 138 adults (73%) (P = .01) had a delay in diagnosis. The median delay in diagnosis was 8 years overall (range 0.5-32 years), 4 years (range 1-13.5 years) in adolescents, and 10 years (range 0.5-32 years) in adults (P = .005). BD were diagnosed in 51% (n = 97) of adult women before age 18, 41% (n = 77) diagnosed after age 18, with the remaining unknown. To ensure that our findings about delayed diagnosis were not due to selection bias, we also compared the delay in diagnosis in adolescents vs adults diagnosed before age 18 years. The delay in diagnosis in adults with age at diagnosis < 18 years was also greater when compared to that in adolescents (median 10 vs 4, IQR 12.5 vs 7 years respectively; P = .0021). There was no statistically significant difference in the age at menarche, BMI and anaemia between both groups.
There were differences in the bleeding phenotype of the adults when compared to adolescents (Table 2) . On bivariate analysis, adults more often reported bleeding after surgery (P = .02), pregnancy/postpartum (P < .0001) and gastrointestinal bleeding (P = .01); bleeding after dental procedures trended towards significance (P = .09). Rate of bleeding per surgery/procedure could not be calculated as data on the total number of surgery/procedures were not collected. Two pregnancies were reported in 2 adolescents vs 279 pregnancies in 108 (56%) adults. Bleeding complications during pregnancy/postpartum were reported by 53% (57/108) of adults when compared to 100% (2/2) of adolescents. Of the study participants, 15% of adolescents (n = 12) and 6% of adults (n = 12) had HMB as the only bleeding symptom (P = .02). Irregular menstrual cycles were reported in 49% (n = 37) and 54% (n = 105) of adolescents and adults respectively (P = .62).
Medical and surgical management of HMB were compared between the groups (Table 2) . A similar proportion of adults and adolescents underwent any therapy for HMB (n = 145; 76% vs n = 59; 75% respectively; P = .78) and medical therapy (n = 151; 79% vs n = 63; 80% respectively; P = 1.0; some patients received more than 1 medication).
On bivariate analysis for HMB management, desmopressin was used more often by adolescents (P = .01), and gynaecologic procedure/ surgery was performed more often in adults (P = .02). No adolescent underwent endometrial ablation, uterine artery embolization or hysterectomy. Antifibrinolytic agents, hormonal therapy, clotting factor products, and blood/plasma products were used similarly in both groups.
On multivariate analysis in the bleeding symptoms model, there was a lower odds of Hispanics (AOR 0.3, 95% CI 0.1-0.7), but higher odds of family history of BD (2.6, 95% CI 1. 
| DISCUSSION
In females with HMB, adults facing more haemostatic challenges may have greater likelihood of being diagnosed with BD and receiving appropriate management. As anovulatory bleeding due to physiologic immaturity is common in the adolescent, an underlying BD may not be considered by the treating physician as a potential cause of HMB.
The bleeding phenotype is different in both age groups as shown in our study, and lack of recognition of bleeding symptoms as due to an underlying BD can lead to increased complications. Our study is the first attempt to compare the bleeding profile, BD diagnoses, medical/surgical/procedural management in adolescents vs adults with HMB. There were more Whites and fewer Hispanics among adults when compared to adolescents, similar to US population patterns. 6 The ethnic distribution between adults and adolescents is comparable to the population of males with haemophilia seen at US HTCs. 7, 8 Adults more often had a family history of a BD. The longer time for evaluation to establish BD diagnosis in adults could have resulted in more referrals and evaluation of their family members. No difference was noted between the 2 groups in the type of BD diagnoses and the sub-types of VWD, the most common BD diagnosed in the study population. PD were reported overall in 4% of the patients. This is likely an underrepresentation, as PFD are reportedly a common cause of HMB. 9, 10 This may be due to underdiagnosis of PD or lack of management of these patients in HTCs.
Proportionately, more adolescents presented with HMB as the only bleeding symptom when compared to adults, which was statistically significant (P = .02). This is most likely due to the younger aged adolescents not experiencing as many haemostatic challenges as adults. Contrary to the common assumption that irregular cycles are more frequent in adolescents, we found irregular menstrual cycles to be equally prevalent in both groups. The findings in our study underline the delay in diagnosis of BD in females with HMB. Overall, there was a delay in diagnosis of 8 years in our study population. This was more pronounced in adults than in adolescents, which was statistically significant. BD were diagnosed in only 51% (n = 97) of adults before age 18. The delay in diagnosis in adults with age at diagnosis < 18 years was greater than that in adolescents. Delay in diagnosis of BD was also statistically significant on multivariate analysis by both models. We suspect the difference in delay in diagnosis in adults vs to the days of bleeding. Oral tranexamic acid (TXA), reportedly more effective than epsilon aminocaproic acid and intranasal desmopressin, 15 has been used extensively for HMB in Europe and Canada, and is available in the US for adults since its FDA approval in 2009. 16 Up to one-third of adolescents in our study used antifibrinolytics although the package insert for TXA states use for age ≥18 years, as the licensure study excluded younger patients. 17 The recent availability in the US and more research in the future on efficacy and safety in adolescents 18 may bring forth increased utilization of TXA in females with HMB.
We found that, overall, gynaecologic surgery/procedure was performed more often in adults when compared to adolescents. This is perhaps because adults having suffered with HMB for decades are reluctant to be on long-term medical therapy opting instead for gynaecological intervention. It is reassuring to note that no adolescent underwent major surgery/procedure for HMB management such as endometrial ablation, uterine artery embolization or hysterectomy.
Medical management is the preferred mode of therapy in adolescents with HMB, with other gynaecologic procedures/surgeries avoided in order to preserve fertility. 12, 13 Our study limitations include the following: this is retrospectively collected, self-reported data based on patient recall which is subject to under-/overestimation of morbidity and lack of accuracy; small sample 
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